5–20 mg/day.
Cuban trials show large LDL reductions, but independent studies outside Cuba find no effect: controversial evidence.
View the study (meta-analysis) →⏱ 3 min read
Policosanol is a mixture of long-chain primary aliphatic alcohols (predominantly octacosanol, triacontanol, dotriacontanol, and others) traditionally extracted from Cuban sugarcane wax, although it can also be obtained from beeswax, rice bran, wheat germ, and other plant sources; its commercial history is closely tied to Cuba, where the state laboratory Dalmer developed a specific sugarcane-derived formulation in the 1980s that was marketed internationally with the promise of lowering cholesterol with an efficacy profile comparable to that of pharmacological statins but with much better tolerability, a promise whose clinical fate deserves an honest and nuanced analysis.
The Cuban clinical trials published during the 1990s and early 2000s showed notable reductions in LDL cholesterol (15-25 percent) and increases in HDL (10-20 percent) with doses of 5-20 milligrams daily for 6-12 weeks, magnitudes comparable to those of low-dose statins and far greater than those of any other natural supplement available; these results generated considerable commercial expectations and positioned policosanol as a "natural" alternative to statins in many markets, a popularity that has persisted in some countries despite later data.
The problem is that independent trials conducted outside Cuba (especially those by the Berthold group published in JAMA in 2006 with 143 German patients) have failed to replicate the lipid-lowering effects documented in the Cuban trials: LDL, HDL, total cholesterol, and triglyceride figures were practically unchanged with doses of 10-80 milligrams daily for 12 weeks compared with placebo in European cohorts with dyslipidemia.
This discrepancy between the Cuban and the independent European trials has not been completely resolved: the hypotheses include differences in the exact composition of the original Cuban product (which might have a different aliphatic alcohol profile from that of international commercial products), differences in the background diet of the populations studied, publication bias, or undetected methodological problems in the original studies; without robust independent replication of the effects, international dyslipidemia treatment guidelines do not include policosanol among the recommended interventions.
The reasonable position today is that policosanol probably has far more modest lipid-lowering effects than those initially reported, possibly null or marginal in European and North American cohorts; people with dyslipidemia who need a significant LDL reduction are better served by interventions with robust and consistent evidence (statins, ezetimibe, fibrates depending on the indication; among supplements: standardized red yeast rice with monacolin K, phytosterols, soluble fiber such as psyllium, or oat beta-glucans) than by policosanol; in people with mild dyslipidemia where a low-cost exploratory intervention is sought, policosanol may have a place with very conservative expectations and laboratory monitoring to verify individual response.
The doses studied range from 5 to 20 milligrams daily, taken with dinner to optimize the effect on nocturnal cholesterol synthesis; the effect, if it exists, appears gradually and requires at least 8-12 weeks for laboratory assessment of response; typical commercial products contain 10 mg per capsule and are generally well tolerated.
Generally well tolerated at the doses studied; the adverse effects described are rare and mild (digestive discomfort, headache, occasionally skin rash or nosebleeds); people taking warfarin-type anticoagulants or antiplatelet drugs, or who have an increased bleeding risk, should be theoretically cautious because of a possible described mild antiplatelet effect; those taking pharmacological statins or fibrates do not need policosanol and will not benefit from the combination; in pregnancy and breastfeeding the data are limited and avoidance is advised as a precaution; people with significant dyslipidemia or elevated cardiovascular risk should use interventions with robustly documented efficacy and should not postpone effective treatments while waiting for a response to a supplement whose clinical efficacy is questioned by the best available independent evidence.
Information, not medical advice. Scientific evidence reflects the quality of the studies.